Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
What’s going on with the Inoviq (ASX:IIQ) share price today?
Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?
BARD1 (ASX:BD1) share price ends stellar day up 41%
BARD1 Life Sciences (ASX:BD1) share price leaps 16% on US patent news
Share Market News
BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update
Here’s why the BARD1 (ASX:BD1) share price is falling 7% today
Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking
BARD1 (ASX:BD1) share price falls 6% on placement update
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Formerly BARD1 Life Sciences Limited (ASX: BD1).
|18 May 2022||$0.55||$0.04||7.84%||141,344||$0.53||$0.57||$0.52|
|17 May 2022||$0.51||$0.00||0.00%||109,324||$0.51||$0.52||$0.51|
|16 May 2022||$0.51||$0.00||0.00%||175,531||$0.53||$0.54||$0.51|
|13 May 2022||$0.51||$-0.05||-8.93%||194,896||$0.56||$0.58||$0.51|
|12 May 2022||$0.56||$0.01||1.82%||205,312||$0.56||$0.57||$0.53|
|11 May 2022||$0.55||$-0.01||-1.77%||132,323||$0.57||$0.57||$0.55|
|10 May 2022||$0.57||$0.01||1.80%||236,446||$0.56||$0.62||$0.56|
|09 May 2022||$0.56||$-0.02||-3.48%||218,237||$0.58||$0.59||$0.56|
|06 May 2022||$0.58||$0.00||0.00%||178,451||$0.58||$0.62||$0.57|
|05 May 2022||$0.58||$0.01||1.77%||352,983||$0.58||$0.59||$0.56|
|04 May 2022||$0.57||$-0.03||-5.08%||210,821||$0.59||$0.61||$0.57|
|03 May 2022||$0.59||$0.02||3.51%||340,330||$0.57||$0.61||$0.57|
|02 May 2022||$0.57||$0.01||1.79%||895,528||$0.60||$0.60||$0.56|
|29 Apr 2022||$0.56||$-0.01||-1.74%||277,760||$0.57||$0.60||$0.56|
|28 Apr 2022||$0.58||$-0.06||-9.52%||457,649||$0.63||$0.63||$0.57|
|27 Apr 2022||$0.63||$-0.04||-6.02%||200,448||$0.64||$0.65||$0.63|
|26 Apr 2022||$0.67||$-0.01||-1.48%||119,110||$0.68||$0.68||$0.63|
|22 Apr 2022||$0.68||$-0.01||-1.46%||211,677||$0.68||$0.69||$0.68|
|21 Apr 2022||$0.69||$-0.01||-1.43%||215,397||$0.73||$0.73||$0.68|
|20 Apr 2022||$0.70||$-0.01||-1.41%||338,826||$0.71||$0.72||$0.70|
|13 May 2022||Philip (Phil) Powell||Buy||20||$10,620||
On-market trade. Average Price
|06 May 2022||Geoffrey Cumming||Buy||32||$20,082||
|02 May 2022||Philip (Phil) Powell||Buy||50||$29,000||
|13 Dec 2021||Geoffrey Cumming||Issued||500||$520,000||
Issue of options. As per announcement on 22/12/2021.
|13 Dec 2021||Allan Cripps||Issued||500||$520,000||
Issue of options.
|13 Dec 2021||Philip (Phil) Powell||Issued||500||$520,000||
Issue of options.
|13 Dec 2021||Robert (Max) Johnston||Issued||500||$520,000||
Issue of options.
|21 Oct 2021||Philip (Phil) Powell||Buy||40||$43,670||
|24 Aug 2021||Philip (Phil) Powell||Buy||19||$29,998||
Participation in share purchase plan.
|24 Aug 2021||Geoffrey Cumming||Buy||19||$29,998||
Participation in share purchase plan.
|24 Aug 2021||Robert (Max) Johnston||Buy||19||$29,998||
Participation in share purchase plan. As per announcement on 27/08/2021
|Mrs Pauline Anne Collinson||Company Secretary||Nov 2001||
Mrs Collinson has worked for the Company for 23 years and has held the position of Company Secretary for 14 years. She is also the Company Secretary of Tanami Gold NL (ASX:TAM).
|Professor Allan Cripps||Non-Executive Director||Jan 2020||
Prof Cripps is an academic, clinical scientist and health services leader, having made contributions in immunology, diagnostics, and health services delivery. From 2005 to 2016, Prof Cripps was the Pro Vice Chancellor (Health) at Griffith University and is currently a research Prof at Griffith University, leading the Mucosal Immunology Research Group within the Menzies Health Institute Queensland. Prof Cripps had near 20 years' experience in the health and pharmaceutical industries before becoming a full-time academic focusing his research on mucosal immunology, respiratory tract infections, vaccine development and diagnostics. He has published over 300 peer reviewed scientific papers, presented at numerous international scientific conferences, received over $17 million in Government and industry grant funding and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. He is a fellow of the Australian Academy of Health and Medical Scientists, the Australian Society for Microbiology, the Australian Institute of Medical Scientists, the Institute of Biomedical Scientists (UK) and the Australasian College of Health Service Management. In 2015 he was awarded the Order of Australia (AO) for distinguished service to tertiary education as a senior administrator and to public health as a leading immunologist, academic and researcher in the area of mucosal immunisation. Prof Cripps is a Non-Executive Director of Neurotech International Limited (ASX: NTI). He was previously Non-Executive Director of Research Australia (2005 to 2012) and the Gold Coast Hospital and Health Services Board (2011 to 2017). Prof Cripps is a member of the Company's Remuneration Committee and Audit & Risk Committee.
|Mr Philip (Phil) John Powell||Non-Executive Director||Jun 2019||
Mr Powell is a Chartered Accountant with experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP) and RMA Global Ltd (ASX: RMY). He was a former Non- Executive Director of PolyNovo Ltd (ASX: PNV). Mr Powell is the Chair of the Company's Audit & Risk Committee
|Mr Geoffrey A. Cumming||Non-Executive ChairmanNon-Executive Director||Jul 2020||
Dr Cumming has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was successful in designing and securing key funding arrangements through a skilful range of capital raising initiatives, including large government grants, partnering and co-development deals. His most recent executive role was as Managing Director / CEO of Anteo Diagnostics Ltd (ASX: ADO). He is currently a Nonexecutive Director of Anteo Diagnostics Ltd and was previously Chairman of Sienna Cancer Diagnostics Ltd and a Nonexecutive Director of Medical Australia Ltd (ASX: MLA). Dr Cumming is the Chair of the Remuneration Committee
|Mr Robert (Max) Maxwell Johnston||Non-Executive Director||Jun 2019||
Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world's largest medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included senior roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Skills Management Institute (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and CentralEastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is currently Non-Executive Chairman of AusCann Group Holdings Ltd (ASX: AC8) and a Non-Executive Director of Medical Developments International Ltd (ASX: MVP). He was a former Non-Executive Director of Enero Group Limited (ASX: EGG) and PolyNovo Ltd (ASX: PNV), and a former NonExecutive Chairman of Probiotec Ltd (ASX: PBP). Mr Johnston is a member of the Company's Remuneration and Audit & Risk Committees
|Dr Leearne Hinch||Chief Executive Officer||Nov 2016||
|Mr Tony Di Pietro||Joint Company SecretaryChief Financial Officer||Jul 2020||
|Leearne Hinch||Chief Executive Officer||
|Dr Gregory Rice||Chief Scientific Officer||
|Tony Di Pietro||Joint Company SecretaryChief Financial Officer||
|The Trust Company Australia Limited <Mof A/C>||6,086,400||6.62%|
|Moggs Creek Pty Ltd <Moggs Creek Super A/C>||4,886,671||5.32%|
|HSBC Custody Nominees (Australia) Limited||4,507,239||4.90%|
|Dr Irmgard Irminger-Finger||4,070,000||4.43%|
|BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||1,740,697||1.89%|
|J P Morgan Nominees Australia Pty Limited||1,239,572||1.35%|
|Traoj Pty Ltd <Traoj A/C>||1,102,933||1.20%|
|Mr Nathan Ryan Wagner||1,010,433||1.10%|
|Supergun Pty Ltd <Bricklanding Super Fund A/C>||1,000,000||1.09%|
|Washington H Soul Pattinson And Company Limited||745,162||0.81%|
|Dr Russell Kay Hancock||700,000||0.76%|
|Worldwise Enterprises Pty Ltd||684,354||0.74%|
|Citicorp Nominees Pty Limited||654,125||0.71%|
|UBS Nominees Pty Ltd||645,162||0.70%|
|Faraday Nominees Pty Limited <Bronte Investment A/C>||600,000||0.65%|
|B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C>||584,516||0.64%|
|Ll&P Pty Ltd <The Andrew Solomons S/F A/C>||574,095||0.62%|
|B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> I||550,788||0.60%|